IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...

The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.

Amgen’s Uplizna (inebilizumab-cdon) has been approved by the US Food and Drug Administration (FDA) as the first treatment for adults with immunoglobulin G4-related disease (IgG4-RD), a rare ...